Heron Therapeutics Inc. (HRTX)

[mo282]

Also general, appa is targeting delayed onset of CINV, ALOXI is the only medication that targets this and its sales last year were 400 million as mentioned before. here is the link below:

http://pharmalicensing.com/public/news/viewNewsML/4288/Oncology_Palonosetron_Approved_in_Japan_Second_Pharmaceutical_Market_Worldwide